Inherited Neuromuscular Disorders: Pathway to Diagnosis
Overview
Authors
Affiliations
Muscle weakness in childhood can be caused by a lesion at any point extending from the motor cortex, brainstem and spinal cord to the anterior horn cell, peripheral nerve, neuromuscular junction and muscle. A comprehensive history and physical examination is essential to aid classification of the neuromuscular disorder and direct gene testing. The more common disorders such as spinal muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy and facioscapulohumeral dystrophy may be diagnosed on direct gene testing based on the history and clinical examination. The congenital myopathies are classified based on structural abnormalities on muscle biopsy, while protein abnormalities on immunohistochemistry and immunoblotting aid classification of the muscular dystrophies. In this review, we provide an approach to diagnosis of a child with weakness, with a focus on the inherited neuromuscular disorders, and the features on history, examination and investigation that help to distinguish between them.
Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.
Luis M, Goes M, Santos F, Mesquita J, Tavares-Ratado P, Tomaz C Pharmaceutics. 2025; 17(1).
PMID: 39861752 PMC: 11768343. DOI: 10.3390/pharmaceutics17010104.
Vermeulen S, Hordijk M, Visser R, Bunnik E J Law Med Ethics. 2023; 51(1):172-180.
PMID: 37226748 PMC: 10209970. DOI: 10.1017/jme.2023.53.
Neurotransmitters Regulation and Food Intake: The Role of Dietary Sources in Neurotransmission.
Gasmi A, Nasreen A, Menzel A, Benahmed A, Pivina L, Noor S Molecules. 2023; 28(1).
PMID: 36615404 PMC: 9822089. DOI: 10.3390/molecules28010210.
Hong S, Kneissl J, Cho A, Kim M, Park S, Lee J J Med Genet. 2022; 59(11):1075-1081.
PMID: 35387801 PMC: 9613860. DOI: 10.1136/jmedgenet-2021-108307.
Irisin treatment improves healing of dystrophic skeletal muscle.
Reza M, Sim C, Subramaniyam N, Ge X, Sharma M, Kambadur R Oncotarget. 2017; 8(58):98553-98566.
PMID: 29228710 PMC: 5716750. DOI: 10.18632/oncotarget.21636.